Investment Rating - The industry investment rating is "In-Line" [6]. Core Viewpoints - The waiver of certain requirements in the Defense Production Act (DPA) by President Trump aims to boost production capacity for critical minerals, including uranium, copper, potash, and gold, as well as munitions and missiles [2][3]. - Waiving the "terms of sales" requirement could allow the US government to offer above-market pricing for critical minerals, potentially incentivizing new projects and contributing to a bifurcation of pricing in certain commodities, particularly rare earths [3][4]. - The report highlights the potential for a mining boom in the US driven by a push to on-shore supply chains, with the recent DPA changes seen as a step towards this goal [4]. Summary by Sections Industry Overview - The report discusses the implications of the DPA changes on the critical minerals market, suggesting that it could lead to higher pricing and increased domestic production [3][4]. Company Focus - MP Materials (EW, PT $23) is identified as well-positioned to benefit from potential above-market pricing for critical minerals [3]. Market Dynamics - The report notes that the changes could accelerate the development of domestic and allied rare earth element supply chains, which are critical for both commercial and national security [3].

Investment Rating - The report assigns an "Overweight" (OW) rating to Akeso with a price target of HK$99.00 by December 2025 [2][5]. Core Insights - Akeso's AK104, a PD-1/CTLA-4 bispecific antibody, has received approval in China for first-line treatment of persistent, recurrent, or metastatic cervical cancer, which is expected to significantly boost sales in China [1][4]. - The report anticipates a global development plan for AK104 to be announced in the second half of 2025, which could attract investor interest [1][4]. - Upcoming catalysts include sales figures for AK104 and AK112, the potential global development plan announcement, and detailed data from the HARMONi studies [4][5]. Summary by Sections Approval and Efficacy - AK104's approval is based on strong results from the Phase 3 COMPASSION-16 study, showing a median overall survival (mOS) not reached in the AK104+chemo cohort compared to 22.8 months in the control group, and a median progression-free survival (mPFS) of 12.7 months versus 8.1 months [4]. Market Potential - The report estimates that AK104 could generate approximately RMB 6 billion in peak sales in China, while AK112 is expected to achieve over RMB 5 billion in peak sales in non-small cell lung cancer (NSCLC) [5]. Valuation - The price target of HK$99.00 is based on a discounted cash flow (DCF) valuation, assuming a terminal growth rate of 3.0% and a weighted average cost of capital (WACC) of 9.4% [6].

Investment Rating - The report maintains an "Overweight" (OW) rating for several key financial companies including AIA, CCB, CMB, Ping An Insurance, Futu, and CITIC Securities [5][6][9]. Core Insights - The report suggests that China may be on the verge of a 1998-1999 Japan-style beta rally, with potential gains of up to 80% as indicated by strategist Wendy Liu [2][3][6]. - The Jinke case, involving a holistic reorganization of a distressed developer, is seen as a significant step towards addressing China's property oversupply and improving recovery rates [2][3][6]. - The report highlights the importance of focusing on "financial survivors" in the current market environment, which includes companies with strong local economic presence [2][3][6]. Detailed Highlights - The Jinke Real Estate debt reorganization, which occurred on May 10-11, is expected to yield a recovery rate more than seven times higher than liquidation [2][3]. - The report emphasizes that if China implements substantial financial sector reforms, it could mirror the conditions that led to the TPX's 80% beta rally in 1998 [6]. - The report notes that long-term money is becoming less optimistic about Chinese banks, with concerns about the sustainability of the current rally and rising questions regarding asset quality risks [6]. Sector Key Newsflow - In Japan, global mutual funds have begun to increase their positions in banks, indicating a potential bear-squeeze rally in the auto sector that could benefit banks [9]. - The report mentions that the MSCI ACWI is near an all-time high, supported by CTAs building long positions across various sectors, particularly in machinery and banks [9]. - The ECB is expected to cut rates by 25 basis points, with no clear signal for future cuts, indicating a cautious approach to monetary policy [13].

Investment Rating - Industry View: In-Line [3] Core Insights - US consumer sentiment and electronics spending intentions improved month-over-month (M/M) in May, attributed to de-escalating tariffs, although both metrics remain negative and volatile [2][7] - The May AlphaWise Consumer Survey indicated the first M/M uptick in consumer sentiment since 2024, reaching a four-month high, while next six-month (N6M) consumer electronics spending intentions also saw a significant increase, reaching a near four-year high [2][8] - Despite the improvements, both consumer sentiment and N6M spending intentions are still in negative territory, indicating that further stabilization in tariff and inflation concerns is necessary for a sustained positive trend [2][8] Summary by Sections Consumer Sentiment - Consumer sentiment improved by 11 points M/M, with a net 6% of consumers expecting the economy to worsen in the next six months, an 11-point improvement from April [11][12] - The household financial situation sentiment also improved, with a net 14% expecting an improvement in the next six months, up 4 points from April [12] Spending Intentions - Next month consumer electronics net spending intentions increased by 5 points M/M to -1%, the highest since February 2023, while PC net spending intentions increased by 7 points to -3% [8][19] - N6M consumer electronics net spending intentions improved by 17 points M/M to -8%, with lower-income households seeing a 15-point uptick to -15% and higher-income households a 25-point increase to +9% [8][30] Tariff Impact - In May, 36% of survey respondents expected to spend less overall in response to tariffs, down 6 points from April, indicating a positive shift due to lower tariff rates [10][32] - Only 13% of consumers reported pulling forward spending due to tariffs, which is lower than other categories like groceries and household staples [10][34]

Investment Rating - The investment rating for Shanghai Putailai New Energy Tech Co Ltd is Equal-weight [5][79]. Core Insights - The price target has been adjusted downwards from Rmb14.00 to Rmb13.50, reflecting a 4% decrease [4][5]. - The bull case price target is now Rmb16.00, down from Rmb17.50, while the bear case target is reduced to Rmb9.70 from Rmb10.00 [4][5]. - The report indicates a 9% reduction in EPS estimates for 2025, 11% for 2026, and 8% for 2027, primarily due to the roll forward of valuation from 2024 to 2025 and a decrease in the target multiple from 15x to 14x [3][8]. Summary by Sections Financial Performance - The company is expected to experience lower revenue forecasts of 22% and 20% for 2025 and 2026, respectively, due to lower-than-expected sales volume of anode materials [8]. - An increase of approximately 2 percentage points in gross profit margin (GPM) and net profit margin for 2025 and 2026 is anticipated, attributed to better-than-expected GPM in 1Q25 and lower SG&A expenses [8][21]. Market Position - Shanghai Putailai has diversified its business across various battery materials, including anodes and separators, but faces challenges due to slower-than-expected global EV demand growth [11]. - The company is currently suffering from impairment losses in its anode materials segment, which is negatively impacting profitability [11]. Valuation Metrics - The valuation of Putailai is based on a P/E ratio of 14x for 2025e, which is considered a historical low, implying a price-to-book (P/B) ratio of approximately 1.4x, higher than its peers in the battery material sector [9][11].

Investment Rating - The report assigns an "In-Line" industry view for the express delivery segment in China [8]. Core Insights - The express delivery segment in China is experiencing escalated deflationary pressure, leading to challenges in earnings growth for most players due to intensified competition and macroeconomic headwinds [3][28]. - Despite short-term pain, the report anticipates faster segment consolidation driven by stronger economies of scale and the asset-heavy nature of the industry, which poses challenges for smaller players [4][35]. - Key indicators for tracking consolidation include market share dynamics, profit share dynamics, capex dynamics, free cash flow, and balance sheet health [11][50]. Summary by Sections Industry Overview - The express delivery segment has faced significant deflationary pressure, with industry average selling prices (ASP) down 8.3% year-over-year in the first four months of 2025 [28][29]. - The concentration ratio (CR8) has improved, indicating a trend towards market consolidation [13][45]. Competitive Landscape - Major players like ZTO and YTO are expected to emerge as winners in the ongoing consolidation, with ZTO showing strong market leadership in volume and profitability [10][78]. - Yunda has seen a decline in market share from 17.2% in January 2022 to 13.3% in April 2025, indicating competitive pressures [43]. Financial Performance - In the first quarter of 2025, Yunda and YTO reported net profit declines of 19.9% and 10% year-over-year, respectively, while ZTO's net profit remained stable due to higher other income [30][33]. - ZTO is the only player with sustained positive free cash flow among its peers, indicating strong operational health [67][68]. Investment Thesis - The report suggests that ZTO and YTO are positioned to benefit from the consolidation, while Yunda faces risks due to thin profit margins and balance sheet pressures [78][83]. - SF is expected to continue its cost efficiency gains, although uncertainties remain regarding its top-line growth [79]. Capex and Cash Flow Dynamics - Capital expenditure (capex) has slowed, with total industry capex peaking in 2021 and declining in subsequent years [59][60]. - Yunda's capex investment has lagged behind peers since 2022, raising concerns about its capacity for sustained growth [60][62].

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The industry is experiencing a relief rally amidst ongoing uncertainty, particularly related to EU tariffs and trade news from China. Credit markets have shown resilience, with a tight trading range following the initial rally [2][4] - Despite a rally and lower realized volatility, options prices in credit have not decreased in tandem with equities, indicating cautious sentiment among credit investors [4] - The upcoming week features significant economic data releases, including ISM Manufacturing and Non-Farm Payrolls, which could impact market sentiment [6] Summary by Sections Market Overview - Credit markets have remained firm, although cash markets lagged behind the tighter moves seen previously. Discounts to NAV have decreased as the roll season approaches [3][10] - The rates market has rallied due to weaker economic data, providing support to credit markets. This may lead to a return to a negatively correlated spread versus rates regime [2][4] Trading Activity - There has been notable trading activity related to junior mezzanine tranches, suggesting interest in decompression trades with potential convex payoffs [5] - Flows in the credit market have been supportive, with asset managers adding risk early in the week, although there was a shift towards selling risk later on [6][11] ETF Flows - Inflows across investment-grade ETFs totaled $800 million, while high-yield ETFs saw inflows of $1.1 billion, indicating strong demand in these segments [11][14] - The report highlights significant trading volumes in iBoxx and HY futures, with open interest increasing substantially compared to the previous year [11][12] Volatility and Spreads - Realized volatility remains elevated despite tight spreads, with the report noting that such conditions are rare. This suggests a fragile state in synthetic credit markets [8] - The report indicates that if spreads hold, implied volatility may soften, while skew remains firm [8] Economic Indicators - The report outlines key upcoming economic indicators that could influence market dynamics, including ISM Manufacturing and Non-Farm Payrolls [6][15]

Investment Rating - The industry view is rated as In-Line [14] Core Insights - In May, the consumer sector underperformed the Sensex after two consecutive months of outperformance, with approximately 60% of the stocks under coverage underperforming [2][3] - Food & Beverages (F&B) stocks were the worst performers, particularly Varun Beverages and Tata Consumer, while Discretionary & Retail stocks saw some outperformance led by IGI (India) and Trent [2][5] - Over the past 12 months, only Discretionary & Retail stocks outperformed the Sensex, with Jubilant and Nykaa being the best performers, while paint stocks, led by Asian Paints, underperformed the most [3][5] Summary by Category Consumer Sector Performance - The consumer sector saw a valuation de-rating relative to their 5-year average multiples, with exceptions like Jubilant, ITC, Marico, and GCPL experiencing re-rating [1][4] - Majority of stocks are trading below their 200-day moving average (DMA), while most are above their 50-DMA, except for Varun Beverages, ABFRL, Asian Paints, Jubilant, Avenue Supermarts, and ITC [3][19] Stock Ratings and Consensus - Recent consensus rating downgrades were most notable for Vedant Fashion, Dabur, Asian Paints, and Avenue Supermarts, while Page and Titan saw upgrades [5] - Key consensus buy ideas include ITC, Varun Beverages, GCPL, Marico, and Trent, while Asian Paints, Berger, Avenue Supermarts, and ABFRL are key sell ideas [5][20] Earnings Estimates - Downward revisions to consensus earnings estimates for F26 and F27 have continued for most companies, with Berger, Page, and Britannia being the only stocks to see positive upward revisions [6][22] - Changes to consensus earnings estimates show a decline for most companies, particularly in the Paints and F&B sectors [22] Valuation Trends - Paint stocks, Trent, Avenue Supermarts, Dabur, and HUL have seen the most de-rating compared to their five-year trailing average valuation multiples [4] - Current P/E multiples for various sectors indicate a significant range, with Paints at 42.5x and F&B at 55.7x, reflecting a premium over their historical averages [15][24]

Investment Rating - The report suggests a positive outlook for Indian equities, indicating that they appear inexpensive and present a long-term investment opportunity despite global uncertainties [1]. Core Insights - The report emphasizes that the Indian market has absorbed significant negative news since September 2024, yet fundamentals remain strong, with expectations of mid- to high-teens earnings growth over the next three to five years [6][8]. - Key catalysts for India include dovish actions from the RBI, potential stimulus through GST rate cuts, and favorable trade deals with the US, while global factors such as US policy and growth rates are also crucial [6][8]. - The report highlights a shift in foreign portfolio positioning towards India, which is seen as a positive sign for future performance [6]. Summary by Sections Macro Stability and Policy - Strong macro stability is noted, with improving terms of trade, a declining primary deficit, and low inflation volatility [6]. - The report indicates that nominal GDP growth is expected to outpace policy rates, which historically correlates with positive stock performance [29][30]. Earnings and Valuations - Earnings growth is projected to be robust, with a forecast of 14.7% YoY growth for Sensex EPS in F2025, increasing to 19.1% in F2026 [84]. - The report suggests that the current P/B multiple implies a 10-year annual return of 9.4%, indicating improved long-term return prospects [66]. Sector Recommendations - The report recommends an overweight position in domestic cyclicals, financials, consumer discretionary, and industrials, while underweighting energy, materials, utilities, and healthcare sectors [6][89]. - Specific stocks highlighted for potential outperformance include Jubilant FoodWorks, Maruti Suzuki, and Bajaj Finance, among others [91]. Market Outlook - The BSE Sensex target is set at 89,000 by June 2026, suggesting a 9% upside potential, with a favorable macroeconomic backdrop assumed [85][86]. - The report outlines three scenarios: a base case of 89,000, a bull case of 100,000, and a bear case of 70,000, reflecting varying assumptions about oil prices, global growth, and domestic policy [86][88].

Investment Rating - The report maintains an "Overweight" rating on Zai Lab (ZLAB) shares, indicating a positive outlook on the stock's performance relative to its peers [2][4]. Core Insights - The ZL-1310 ASCO phase 1a/1b update demonstrates a compelling efficacy and safety profile, highlighting its differentiated potential in treating extensive-stage small cell lung cancer (ES-SCLC) [4]. - The 1.6 mg/kg cohort shows a 79% unconfirmed overall response rate (ORR) and a 100% disease control rate (DCR) in patients with one prior line of therapy, suggesting strong efficacy [4]. - The report anticipates that Zai Lab will initiate a pivotal trial in second-line SCLC later this year, which could further validate the drug's potential [4]. - The report estimates that assuming approximately $500 million in net sales/royalties to Zai Lab, this could add mid-single digits to the valuation of ZLAB shares [4]. Summary by Sections Efficacy and Safety Profile - The ZL-1310 trial data indicates a 67% unconfirmed ORR and a 97% DCR in the overall population of 33 patients [4]. - The safety profile is described as clean, with no discontinuations and Grade 3+ treatment-related adverse events (TRAEs) at 6%, primarily consisting of anemia (2%) and neutropenia (4%) [4]. Competitive Landscape - The report notes that Imdelltra (tarlatamab) has a ~40% ORR in relapsed/refractory ES-SCLC, positioning ZL-1310 favorably in comparison [4]. Future Outlook - Zai Lab's existing commercial franchise and upcoming product launches, along with a growing internal pipeline including ZL-1310, support the reiterated Overweight rating [4].